In options trading, there is something that I call the guacamole dilemma. It centers around whether too much of a good thing is really that good. When the markets drop 2-3%, which we have seen can happen within a week’s time, is it a good time to buy that dip? If you look at the…
Details
After kicking off this week’s webinar with my state of the market update and talking about some great plays, I introduced my good friend Brian Gilmartin, a strategist at Trinity Asset Management. He shared his words of wisdom around the upcoming earnings season and the best play ideas and gave a great synopsis of what…
Details
After a couple weeks off, our webinars were back in full force today. I covered volatility and sentiment indicators – both hot topics right now as we try to keep tabs on the markets – and I touched upon some areas where traders have been suffering. Our biggest discussion was around 3 charts that are…
Details
I received the following email from one of our most active Explosive Options Chat Room members, Ketan. Here is his story: I love my mom a lot. She has done so much for me, and she always had a dream of seeing me succeed and sitting in a Mercedes Benz that I own. Yes, a…
Details
If the charts are to be believed, the path of least resistance for Biogen, Regeneron, Celgene and Gilead is up-up-up. In fact, these 4 biotech stocks are known as Jim Cramer’s “4 Horsemen of Biotech.” Although these stocks’ fundamentals have appeared bullish to Cramer for quite some time, he often turns to technicals for further…
Details
That was not a bad first half of 2014! The SPX 500 is definitely the big winner, as it is up a solid 6% and was able to hold steady every month since January. It obviously proved the old adage of a down January wrong (“As January goes, so goes the rest of the year”).…
Details
Freeport McMoRan Copper & Gold (FCX) has been expanding their portfolio to include oil discovery, natural gas, and drilling, and with this diversification, they have gone through a complete makeover. I’ll cut right to the chase: their chart shows a strong move upward that may continue. The stock has enjoyed strong turnover and a blitz…
Details
Admitting you are wrong is really, really hard – no matter what the situation. When it comes to options trading though, you have to be careful. Many traders and investors let their ego get in the way rather than admit they made a mistake – and that leads them down a very calamitous road. I…
Details
Bob got the pre-holiday session started with his state of the market address and talked about some recent trading ideas. He taught some lessons about the MACD, how it’s used and how he uses it and why it is a great tool for predicting options. Bob also showed the better uses of weekly options. He…
Details
Bryan Ashenberg joined me for a mid-year Trifecta Stocks update. So far in 2014, we are lagging – that’s part of the game – but we are making big strides and are looking to enjoy some nice gains over the coming months. We talked about Amazon, which didn’t quite make the quant cut, so we…
Details